Article Text

Download PDFPDF
Immunodeficiency screening: is disruption of the BCG programme really warranted?
  1. Sam J Oddie1,
  2. Helen Mactier2
  1. 1 Bradford Neonatology, Bradford Royal Infirmary, Bradford, UK
  2. 2 President, British Association of Perinatal Medicine, Glasgow, UK
  1. Correspondence to Dr Sam J Oddie, Bradford Neonatology, Bradford Royal Infirmary, Bradford BD16 1AR, UK; Sam.oddie{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

Many UK paediatricians and neonatologists will be aware that the National Screening Committee (NSC) is piloting screening for severe combined immunodeficiency (SCID) from September 2021. Lymphopaenia will be detected in newborn bloodspots using T cell receptor excision circles, a DNA biomarker for T cells. This is expected to be a sensitive but poorly specific screening test with SCID diagnosed in around 18 newborns in the UK and an estimated 260 newborns screen positive annually.1 Currently, one-third of cases are diagnosed early through a family history …

View Full Text


  • Twitter @HMactier

  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.